por John R. Fischer
, Senior Reporter | September 24, 2019
Provision Healthcare is branching out with the development of a new proton therapy center in Kansas City, Kansas.
Named the Provision CARES Cancer Center and Proton Therapy Center, the facility is an expansion of the Provision Cares Cancer Network and will be located in the Lenexa community of the city to serve local patients and those in surrounding regions.
"The Kansas City Provision CARES Cancer Center and Proton Therapy Center will be the fourth Provision CARES center in the U.S. as Provision Healthcare continues to develop the network and pursue our mission to make advanced cancer care and proton therapy more accessible by developing cancer centers and proton therapy centers in the U.S., Asia, and around the world," said Dr. Terry Douglass, Chairman and CEO of Provision Healthcare, in a statement.
Special-Pricing Available on Medical Displays, Patient Monitors, Recorders, Printers, Media, Ultrasound Machines, and Cameras.This includes Top Brands such as SONY, BARCO, NDS, NEC, LG, EDAN, EIZO, ELO, FSN, PANASONIC, MITSUBISHI, OLYMPUS, & WIDE.
The three-treatment room center will comprise technology supplied by ProNova Solutions, a Provision HealthCare company, including its ProNova SC360. The solution consists of a 360 compact gantry and super conducting magnets, as well as pencil-beam scanning and advanced imaging with cone-beam CT, all in a compact design.
The Provision CARES Cancer Center and Proton Therapy Center is expected to treat approximately 1,000 patients annually, with other medical office space in development offering additional complementary cancer services outside the center.
The announcement follows the recent initiation of treatment on patients
at the New York Proton Center, which opened this past summer
. The Provision CARES Cancer Center and Proton Therapy Center is not expected to be the only one in the sunflower state, with the University of Kansas Health System recently signing a contract for and paying IBA
for a ProteusOne Solution.